Novartis hat trick for Goldman

Goldman Sachs secured its third multi-billion-euro mandate from Novartis today after the Swiss pharmaceutical giant agreed a $5.1bn (€4.3bn) acquisition of Chiron, a US vaccine maker. Goldman has advised on €10bn worth of Novartis acquisitions this year. The bank is sole adviser on the Chiron deal.

In February the bank was sole adviser to Novartis on its €4.35bn purchase of Hexal, a German pharmaceuticals group. The same month Goldman worked on Novartis' $1.7bn bid for Eon Labs of the US.

WSJ Logo
Pro Bono or Pro Nono? Law Firms Split on Fulfilling Deals With TrumpExternal link

Pro Bono or Pro Nono? Law Firms Split on Fulfilling Deals With Trump